Navigation Links
TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
Date:5/18/2008

tes for patients with EE. In one study, the life table analysis showed that 93 percent and 95 percent of TAK-390MR patients (60 mg and 90 mg, respectively) experienced healing versus 92 percent of lansoprazole 30 mg patients. The crude rate analysis showed that 87 percent of 60 mg and 89 percent of 90 mg TAK-390MR patients experienced healing versus 85 percent of lansoprazole 30 mg patients.

In a second study, the life table analysis demonstrated that 92 percent of both 60 mg and 90 mg patients experienced healing versus 86 percent of patients on lansoprazole 30 mg. The crude rate evaluation showed that 85 percent and 86 percent of patients treated with TAK-390MR (60 mg and 90 mg, respectively) experienced healing versus 79 percent of patients taking lansoprazole 30 mg. The results for TAK-390MR 90 mg were statistically significantly higher than lansoprazole 30 mg in both studies using crude rate analysis.

The most frequent treatment-related adverse event (AE) for patients in the combined healing studies was diarrhea, which occurred in similar rates across groups (three percent for TAK-390MR 60 mg and 90 mg, versus two percent for lansoprazole 30 mg).

"Findings from both studies demonstrated that patients taking TAK-390MR 60 mg and 90 mg showed numerically higher overall healing than those taking lansoprazole with a similar rate of AEs across groups," said Dr. Prateek Sharma, professor of medicine, gastroenterology section, University of Kansas School of Medicine.

Maintenance of Healed Erosive Esophagitis

TAK-390MR was compared to placebo in a double-blind, randomized, controlled trial in patients with confirmed healing of EE. A total of 445 patients were enrolled in the global, six-month study. The primary objective was to evaluate the overall maintenance rate of healed EE after once-daily administration of TAK-390MR 30 mg, 60 mg, or placebo. A secondary objective was to evaluate the frequency of heartburn over the six-month study
'/>"/>

SOURCE TAP Pharmaceutical Products Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... U.S. Food and Drug Administration (FDA) approved ... of INTELENCE ® (etravirine), a non-nucleoside reverse transcriptase ... virus (HIV-1) in treatment-experienced adults with resistance to an ... The recommended oral dose of INTELENCE tablets is 200 ...
... KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... with its subsidiary collectively as the "Group" - 801.HK), ... announce that the Company has obtained the approvals from ... Futures Bureau for its proposed offering and listing of ...
Cached Medicine Technology:FDA Approves New Dosage Strength for INTELENCE® 2FDA Approves New Dosage Strength for INTELENCE® 3FDA Approves New Dosage Strength for INTELENCE® 4FDA Approves New Dosage Strength for INTELENCE® 5Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering 2
(Date:9/19/2014)... 19, 2014) Shahram Majidi, M.D., a second-year ... George Washington University School of Medicine and Health ... Heart Association to study the presence of diffuse ... hemorrhage (ICH). , "According to epidemiological studies, intracerebral ... all strokes, but is the least treatable form ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... 19, 2014 BCC Research reveals in ... GLOBAL MARKETS , the global market for human antifungal ... by 2018, with a five-year compound annual growth rate ... growing at a steady 3.8% CAGR. , Given the ... sales, coupled with the incidence of increasing mortality and ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Capital ... Reed Ference, is excited to announce the latest ... periodontal disease, gingivitis and those needing dental implants. ... LANAP® laser treatment removes the fear factor normally ... stitches, less discomfort and bleeding make, this procedure ...
(Date:9/19/2014)... Singulair, developed by Merck, is a CysLT1 ... (LTD4). LTD4 belongs to the family of Cys-LTs, which ... mast cells and eosinophils, and which bind to the ... there are higher concentrations of Cys-LTs in the airways ... production of CysLTs is increased in asthmatics, particularly during ...
Breaking Medicine News(10 mins):Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4
... disease (COPD) are more likely to suffer worse consequences ... due to be presented at the American Thoracic Society ... play a role in the increased death rate seen ... M.D., Assistant Professor of Medicine at the University of ...
... as many patients in the chronic disease management programs ... Boon Wan who was addressing he third National Disease ... of death and human suffering remains a fact as ... could be an effective tool in such circumstances. To ...
... socioeconomic status have a higher level of stress hormones in ... the newest issue of Psycosomatic Medicine, this increased level is ... study does not have to do with poverty, per se,’ ... Carnegie Mellon University. He said the purpose of the study ...
... the popular belief that the effect of war and ... soldier’s partner and children//. It highlights that war trauma ... ,Psychiatrist Arend Veeninga, in the Dutch monthly ... to the theory that ‘war trauma is infectious’. ...
... Researchers at Baylor University Medical Center at Dallas and ... to introduce insulin genes into the pancreas//. , ... (blood sugar) to enter the cells of the body ... ultrasound-targeted micro bubble destruction (UTMD), delivers these insulin genes ...
... the Internet, cancer patients find it hard to locate ... new study has found. Surprisingly, most cancer patients seek ... cancer information on their own, reveals the study conducted ... ,Despite the ease and availability of Internet ...
Cached Medicine News:Health News:Lung Disease More Severe In Women Than Men 2Health News:Lung Disease More Severe In Women Than Men 3Health News:Hormone Levels Increase Due To Socioeconomic Stress 2Health News:Bubble Technique on the cards For Treatment of Type I diabetes 2Health News:Internet Searches Fail To Give Useful Information To Cancer Patients 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: